Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $6.6 million.

  • Tango Therapeutics' Share-based Compensation fell 770.41% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 607.28%. This contributed to the annual value of $28.9 million for FY2024, which is 5145.97% up from last year.
  • Tango Therapeutics' Share-based Compensation amounted to $6.6 million in Q3 2025, which was down 770.41% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Share-based Compensation peaked at $7.5 million during Q2 2024, and registered a low of $950000.0 during Q1 2021.
  • In the last 5 years, Tango Therapeutics' Share-based Compensation had a median value of $4.9 million in 2023 and averaged $4.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 72057.42% in 2021, then tumbled by 1284.16% in 2025.
  • Tango Therapeutics' Share-based Compensation (Quarter) stood at $2.3 million in 2021, then soared by 67.7% to $3.8 million in 2022, then grew by 28.9% to $4.9 million in 2023, then surged by 52.94% to $7.5 million in 2024, then decreased by 11.22% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $6.6 million for Q2 2025, and $7.3 million during Q1 2025.